The effect of denosumab administration on bone metabolism for treatment of spinal metastasis
- 1 January 2021
- journal article
- research article
- Published by Elsevier in Journal of Orthopaedics
- Vol. 23, 216-218
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Clinical outcome for patients of solitary bone only metastasisJournal of Orthopaedic Science, 2016
- New prognostic factors and scoring system for patients with skeletal metastasisCancer Medicine, 2014
- Clinical significance of serum BAP, TRACP 5b and ICTP as bone metabolic markers for bone metastasis screening in lung cancer patientsClinica Chimica Acta, 2013
- Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trialThe Lancet, 2012
- Evaluation of bone metabolic markers in breast cancer with bone metastasisBreast Cancer, 2001
- INCIDENCE OF SKELETAL COMPLICATIONS IN PATIENTS WITH BONE METASTATIC PROSTATE CANCER AND HORMONE REFRACTORY DISEASE: PREDICTIVE ROLE OF BONE RESORPTION AND FORMATION MARKERS EVALUATED AT BASELINEJournal of Urology, 2000
- Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline.2000
- Markers of bone turnover for the management of patients with bone metastases from prostate cancerBritish Journal of Cancer, 2000